Maze Therapeutics Announces Board and Compensation Changes
Ticker: MAZE · Form: 8-K · Filed: Sep 2, 2025 · CIK: 1842295
| Field | Detail |
|---|---|
| Company | Maze Therapeutics, Inc. (MAZE) |
| Form Type | 8-K |
| Filed Date | Sep 2, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $500,000, $50,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation
TL;DR
Maze Therapeutics shakes up board, updates exec pay. Big changes coming?
AI Summary
Maze Therapeutics, Inc. announced on September 2, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company reported the departure of a director and the election of a new director, alongside updates to the compensatory arrangements for certain officers.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, impacting investor confidence.
Risk Assessment
Risk Level: medium — Board and executive changes, especially without detailed reasons, can introduce uncertainty about the company's future direction and stability.
Key Players & Entities
- Maze Therapeutics, Inc. (company) — Registrant
- September 2, 2025 (date) — Date of earliest event reported
FAQ
Who is the departing director and why did they leave?
The filing states the departure of a director but does not name the individual or provide a reason for their departure.
Who is the newly elected director?
The filing indicates the election of a new director but does not provide their name.
What specific changes were made to compensatory arrangements?
The filing mentions updates to compensatory arrangements for certain officers but does not detail the specific changes.
Are there any financial implications associated with these board and compensation changes?
The filing does not disclose any direct financial implications related to the board or compensation changes.
When did these changes become effective?
The changes reported in this 8-K filing were effective as of September 2, 2025.
Filing Stats: 1,069 words · 4 min read · ~4 pages · Grade level 12.1 · Accepted 2025-09-02 07:00:23
Key Financial Figures
- $0.001 — ch registered Common Stock - par value $0.001 per share MAZE The Nasdaq Stock Mar
- $500,000 — s: (i) an initial annual base salary of $500,000 per year, (ii) an annual discretionary
- $50,000 — lary, (iii) a one-time sign-on bonus of $50,000, which is subject to clawback if his se
Filing Documents
- d11864d8k.htm (8-K) — 26KB
- 0001193125-25-193353.txt ( ) — 142KB
- maze-20250902.xsd (EX-101.SCH) — 3KB
- maze-20250902_lab.xml (EX-101.LAB) — 18KB
- maze-20250902_pre.xml (EX-101.PRE) — 11KB
- d11864d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date:September 2, 2025 By: /s/ Courtney Phillips Courtney Phillips General Counsel and Corporate Secretary